Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Gains from Investment Securities (2017 - 2024)

Historic Gains from Investment Securities for Vistagen Therapeutics (VTGN) over the last 10 years, with Q1 2024 value amounting to -$7200.0.

  • Vistagen Therapeutics' Gains from Investment Securities fell 130000.0% to -$7200.0 in Q1 2024 from the same period last year, while for Mar 2024 it was -$6000.0, marking a year-over-year decrease of 10769.23%. This contributed to the annual value of -$6000.0 for FY2024, which is 10085.4% down from last year.
  • Per Vistagen Therapeutics' latest filing, its Gains from Investment Securities stood at -$7200.0 for Q1 2024, which was down 130000.0% from $400.0 recorded in Q4 2023.
  • In the past 5 years, Vistagen Therapeutics' Gains from Investment Securities ranged from a high of $76700.0 in Q4 2022 and a low of -$9900.0 during Q3 2022
  • Moreover, its 5-year median value for Gains from Investment Securities was $750.0 (2021), whereas its average is $4950.0.
  • Per our database at Business Quant, Vistagen Therapeutics' Gains from Investment Securities skyrocketed by 757000.0% in 2022 and then crashed by 130000.0% in 2024.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Gains from Investment Securities stood at $3200.0 in 2020, then plummeted by 68.75% to $1000.0 in 2021, then surged by 7570.0% to $76700.0 in 2022, then plummeted by 99.48% to $400.0 in 2023, then plummeted by 1900.0% to -$7200.0 in 2024.
  • Its last three reported values are -$7200.0 in Q1 2024, $400.0 for Q4 2023, and $400.0 during Q3 2023.